SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Precision Antibody™ announced today its selection by Science Applications International Corporation-Frederick (SAIC-F) to provide antibody and antigen characterization, including surface plasmon resonance (SPR) analysis, for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" (CPTC) initiative (www.proteomics.cancer.gov). A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

Precision Antibody previously won a contract with SAIC-F to develop custom monoclonal antibodies for the CPTC initiative. The new contract calls for Precision Antibody to assist SAIC-F with the antigen and antibody characterizations of some of the newly developed CPTC monoclonal antibodies. Specifically, Precision Antibody will provide full kinetic analyses of antibody-antigen interactions by determining real-time on- (ka) and off- (kd) rates and affinity constants (KD) of selected antibody-antigen pairs and other characterizations, including ELISA, Western blot analyses, antibody isotyping, and antigen characterization by SDS-PAGE.

The antibody characterization contract award was the result of a competitive bidding process among private companies that offer Biacore protein interaction analysis capabilities and was managed by SAIC-F, a wholly owned subsidiary of SAIC that operates the National Cancer Institute's leading center for cancer research in Frederick, Maryland.

"We are delighted that SAIC-Frederick has selected Precision Antibody to provide characterization for these high-quality reference antibodies," said Jun Hayashi, Ph.D., Vice President of Precision Antibody. "Our goal is to help the CPTC characterize antibodies and ultimately select the best antibodies that will minimize proteomic experimental variability from run to run, instrument to instrument, and lab to lab. We are excited to accelerate NCI's creation of a public resource of gold-standard antibodies to advance proteomics research."